When is oritavancin used to treat enterococcal infections?

Updated: Jun 10, 2021
  • Author: Susan L Fraser, MD; Chief Editor: John L Brusch, MD, FACP  more...
  • Print
Answer

In August 2014, the FDA approved oritavancin for acute bacterial skin and skin structure infections (ABSSSI). Oritavancin is a lipoglycopeptide antibiotic. Susceptible gram-positive isolates include S aureus (including methicillin-susceptible S aureus and MRSA methicillin-resistant S aureus [MRSA] isolates), S pyogenes, S agalactiae, S dysgalactiae, S anginosus group (S anginosus, S intermedius, S constellatus), and E faecalis (vancomycin-susceptible isolates only). It is administered as an IV infusion over 3 hr as a one-time single-dose of 1200 -mg. Results from the SOLO I and II trials showed a single- dose of oritavancin was noninferior to twice daily vancomycin for 7-10 days for treating ABSSSI. [56]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!